Literature DB >> 27652593

Bleeding complications and mortality in warfarin-treated VTE patients, dependence of INR variability and iTTR.

Per Sandén1, Henrik Renlund, Peter J Svensson, Anders Själander.   

Abstract

High quality of warfarin treatment is important to prevent recurrence of venous thromboembolism (VTE) without bleeding complications. The aim of this study was to examine the effect of individual time in therapeutic range (iTTR) and International Normalised Ratio (INR) variability on bleeding risk and mortality in a large cohort of well-managed patients with warfarin due to VTE. A cohort of 16612 patients corresponding to 19502 treatment periods with warfarin due to VTE between January 1, 2006 and December 31, 2011 was retrieved from the Swedish national quality register AuriculA and matched with the Swedish National Patient Register for bleeding complications and background characteristics and the Cause of death register for occurrence and date of death. The rate of bleeding was 1.79 (confidence interval (CI) 95 % 1.66-1.93) per 100 treatment years among all patients. Those with poor warfarin treatment quality had a higher rate of clinically relevant bleeding, both when measured as iTTR below 70 %, 2.91 (CI 95 % 2.61-3.21) or as INR variability over the mean value 0.85, 2.61 (CI 95 % 2.36-2.86). Among those with both high INR variability and low iTTR the risk of clinically relevant bleeding was clearly increased hazard ratio (HR) 3.47 (CI 95 % 2.89-4.17). A similar result was found for all-cause mortality with a HR of 3.67 (CI 95 % 3.02-4.47). Both a low iTTR and a high INR variability increase the risk of bleeding complications or mortality. When combining the two treatment quality indicators patients at particular high risk of bleeding or death can be identified.

Entities:  

Keywords:  INR variability; TTR; all-cause mortality; bleeding; venous thromboembolism; warfarin

Mesh:

Substances:

Year:  2016        PMID: 27652593     DOI: 10.1160/TH16-06-0489

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Management of Patients with Acute Subdural Hemorrhage During Treatment with Direct Oral Anticoagulants.

Authors:  Christopher Beynon; Steffen Brenner; Alexander Younsi; Timolaos Rizos; Jan-Oliver Neumann; Johannes Pfaff; Andreas W Unterberg
Journal:  Neurocrit Care       Date:  2019-04       Impact factor: 3.210

2.  Best quality indicator of vitamin K antagonist therapy to predict mortality and bleeding in haemodialysis patients with atrial fibrillation.

Authors:  Paola Rebora; Marco Moia; Monica Carpenedo; Maria G Valsecchi; Simonetta Genovesi
Journal:  Blood Transfus       Date:  2020-12-03       Impact factor: 3.443

3.  Prediction of bleeding risk in patients taking vitamin K antagonists using thrombin generation testing.

Authors:  Saartje Bloemen; Suzanne Zwaveling; Hugo Ten Cate; Arina Ten Cate-Hoek; Bas de Laat
Journal:  PLoS One       Date:  2017-05-04       Impact factor: 3.240

4.  Clinical usefulness of the SAMe-TT2R2 score: A systematic review and simulation meta-analysis.

Authors:  Jasper H A van Miert; Sarah Bos; Nic J G M Veeger; Karina Meijer
Journal:  PLoS One       Date:  2018-03-13       Impact factor: 3.240

5.  Triple therapy after PCI - Warfarin treatment quality and bleeding risk.

Authors:  Daniel Wadell; Jens Jensen; Erling Englund; Anders Själander
Journal:  PLoS One       Date:  2018-12-18       Impact factor: 3.240

6.  Cost saving analysis of specialized, eHealth-based management of patients receiving oral anticoagulation therapy: Results from the thrombEVAL study.

Authors:  Lisa Eggebrecht; Paul Ludolph; Jürgen H Prochaska; Philipp S Wild; Sebastian Göbel; Marina Panova-Noeva; Natalie Arnold; Markus Nagler; Christoph Bickel; Michael Lauterbach; Roland Hardt; Hugo Ten Cate; Karl J Lackner; Christine Espinola-Klein; Thomas Münzel
Journal:  Sci Rep       Date:  2021-01-28       Impact factor: 4.379

Review 7.  Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies.

Authors:  Wern Yew Ding; Stephanie Harrison; Dhiraj Gupta; Gregory Y H Lip; Deirdre A Lane
Journal:  Front Med (Lausanne)       Date:  2020-02-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.